Sanjay Mistry, PhD

Sanjay is Vice President, Venture Investments, New Company Creation for Johnson & Johnson Innovation – JJDC Inc. He focuses on investments that create companies based on internal or externally derived innovations that can deliver transformational healthcare solutions based on new growth platforms. He is currently on the Boards of Rapport Therapeutics (Director), TRexBio (Director) and Manifest Technologies (Observer). Other past company creations include Provention Bio (acquired by Sanofi), Fusion Pharmaceuticals (public – FUSN) and Aro Therapeutics (private).

Sanjay also spent 5 years as an investor with healthcare venture capital firm Quaker Partners, where he focused on biopharmaceuticals and diagnostic/tools investing. Key investments included Durata Therapeutics (acquired by Actavis), RainDance Technologies (acquired by BioRad) and Rapid Micro Biosystems (public – RPID).

Prior to joining JJDC he held several roles across J&J including being the Head of JLABS at San Diego, Senior Finance Director, Business Operations for Janssen R&D and a Co-founder of an internal venture at Centocor which developed a Phase 2b ready cell therapy for age related macular degeneration. Prior to this he was an entrepreneur at Morphogen Pharmaceuticals, where he led pre-clinical development of cell therapies for cardiovascular and neurological indications.

Sanjay attained a PhD in Pharmacology & MSc. in Clinical Pharmacology from the University of Aberdeen and a BSc. in Biomedical Sciences/Pharmacology from Nottingham Trent University.